EXPERT REACTION: mRNA COVID-19 vaccines may be linked to inflammation of the heart muscle

Publicly released:
International; NSW; VIC; QLD

Two studies have found cases of myocarditis, an inflammation of the heart muscle, developing within days of people having both the Pfizer and Moderna COVID-19 mRNA vaccines. One study documents four cases that developed one to five days after receiving the second dose of an mRNA-based COVID-19 vaccine, while the second study from the US military describes 23 cases that occurred four days after vaccination, 20 of these cases occurred after the second dose. The studies do not show the vaccines caused the condition, just that the conditions occurred soon after vaccination and could therefore possibly be linked.

Media release

From: JAMA

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination

What The Study Did: This study describes four patients who presented with acute myocarditis after mRNA COVID-19 vaccination.

Authors: Raymond J. Kim, M.D., of the Duke Cardiovascular Magnetic Resonance Center in Durham, North Carolina, is the corresponding author.

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of US Military

What The Study Did: Researchers describe myocarditis presenting after COVID-19 mRNA vaccination in 23 patients within the Military Health System.

Authors: Jay Montgomery, M.D., of Walter Reed National Military Medical Center in Bethesda, Maryland, and Margaret Ryan, M.D., M.P.H., of the Naval Medical Center San Diego, are the corresponding authors.

Expert Reaction

These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.

Dr Roger Lord is a senior lecturer (Medical Sciences) with the Faculty of Health Sciences at The Australian Catholic University and Visiting Research Fellow with The Prince Charles Hospital (Brisbane)

The recent publications in the Journal of the American Medical Association (JAMA) on the development of acute myocarditis following mRNA COVID-19 vaccine are interesting but difficult to directly infer causality.

Coxsackie B virus has previously been implicated in the development of myocarditis and experimental autoimmune models of the disease involve non-specific stimulation of the immune system to induce the condition. 

In the publication by Kim HW et al, the four patients described that developed acute myocarditis had elevated white blood cell counts (WBC) on admission to hospital (two were abnormal). 

Testing for COVID-19 infection and other respiratory viruses indicated a negative response however the possibility of infection with other pathogens to account for elevated WBC was not determined. 

Did these very rare cases of acute myocarditis arise from the combination of an infection and non-specific immune stimulation provided by the vaccination process? 

The authors clearly establish the development of myocarditis in the four patients but later indicate that methods for testing for COVID-19 infection or other respiratory viruses were not foolproof and that the development of myocarditis with non-mRNA COVID-19 vaccines remains unknown. 

Collectively, the chances of developing acute myocarditis after receiving a COVID-19 mRNA vaccine is extremely rare and this adverse event may involve other factors such as an underlying infection to initiate the process.

Last updated:  29 Jun 2021 11:04am
Contact information
Contact details are only visible to registered journalists.
Declared conflicts of interest None declared.
Professor Chris Semsarian is a cardiologist at the University of Sydney, Royal Prince Alfred Hospital.

The two studies describe a small number of people, mainly young males, with inflammation of the heart muscle, so-called myocarditis, in the setting of Pfizer/Moderna COVID-19 vaccination.

The two studies show an association of vaccination with myocarditis but they certainly do not imply causation.

The incidence of myocarditis in these studies is exceedingly rare amongst those who are vaccinated, and is infinitely outweighed by the striking benefits of COVID-19 vaccination in preventing cardio-respiratory failure and death, especially in those with pre-existing cardiovascular disease.

The complication of myocarditis is exceedingly rare in these two studies - 27 cases (23+4) amongst over 3 million vaccinated.

The studies should remind clinicians that all vaccines have rare complications, and in this case, cardiac symptoms such as chest pain or shortness of breath should be investigated if they occur post-vaccination.

Despite exceedingly rare potential complications, population-wide vaccination remains the key to overcome the COVID-19 pandemic.

Last updated:  29 Jun 2021 11:03am
Contact information
Contact details are only visible to registered journalists.
Declared conflicts of interest None declared.
Dr Daryl Cheng is the Medical Lead of the Melbourne Vaccine Education Centre.

Although reported myocarditis or pericarditis cases after COVID-19 mRNA vaccinations are above expected background rates of both these conditions; they are a rare occurrence. In particular, more cases have been reported in the young adult male subgroup. Acute chest pain in the first few days after mRNA vaccination should prompt people to seek medical review. 

Thankfully, the overwhelming majority of overseas reported cases thus far have been mild and have made a rapid recovery. Importantly, COVID-19 mRNA vaccines remain highly effective at preventing COVID-19 disease and these rare adverse events pale in comparison to the serious long term cardiac injury and morbidity that is caused by SARS-CoV-2 infection. 

Detecting safety signals such as myocarditis/pericarditis demonstrate that both Australian and international vaccine safety surveillance systems are robust and constantly adapting to the latest available data. The main safety challenge with a large population-wide rollout is detecting and responding to signals such as these which were not evident in a clinical trial. The TGA and state-based surveillance systems, such as SAEFVIC [Surveillance of Adverse Events Following Vaccination In the Community] in Victoria, are actively identifying and providing information for groups like ATAGI [Australian Technical Advisory Group on Immunisation] to come to clinical safety decisions.

Australians want to know that our rollout is underpinned by a robust safety vaccine system, and any previous and future changes to the rollout system should be viewed in this context.

Last updated:  29 Jun 2021 11:02am
Contact information
Contact details are only visible to registered journalists.
Declared conflicts of interest None declared.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Paper 1 - Please link to the article in online versions of your report (the URL will go live after the embargo ends).
Research JAMA, Web page paper -2 Please link to the article in online versions of your report (the URL will go live after the embargo ends).
Journal/
conference:
JAMA Cardiology
Research:Paper
Organisation/s: Duke Cardiovascular Magnetic Resonance Center, USA, Defense Health Agency, USA
Funder: See papers for funding and COIs
Media Contact/s
Contact details are only visible to registered journalists.